In a clinical trial, the combination of capmatinib with EGFR-TKIs is determined as a promising treatment option for patients with EGFR-mutated, MET-dysregulated NSCLC and particularly for patients with MET-amplified tumors [58]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.